T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

  • End date
    Aug 1, 2022
  • participants needed
  • sponsor
    University of Arizona
Updated on 26 January 2021
breast cancer
her2/neu-positive breast cancer


This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival compared to single agent T-DM1in patients with metastatic HER2 positive breast cancer


This is a multi-center, randomized, phase II study of T-DM1 with or without palbociclib in the treatment of patients with metastatic HER2-positive breast cancer. Patients will be randomized 1:1 to T-DM1 with or without palbociclib.

Hypotheses: Combination of T-DM1 with palbociclib improves progression free survival compared to single agent T-DM1

Primary objective: Compare progression free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1

Secondary objectives i) Compare response rates between both treatment arms ii) Compare overall survival between both treatment arms

Correlative objectives i) Investigate predictive biomarkers of response in blood and archived tumor tissue ii) Investigate mechanisms of resistance for palbociclib in blood and tumor tissue

Condition Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Cancer, Recurrent Breast Cancer, Breast Cancer Diagnosis, Stage IV Breast Cancer, HER2 Positive Breast Carcinoma, Breast Cancer Stage, breast carcinoma, her2/neu-positive breast cancer, her2-positive breast cancer, cancer, breast, breast cancer stages, breast cancer staging, stage breast cancer
Treatment Palbociclib, T-DM1
Clinical Study IdentifierNCT03530696
SponsorUniversity of Arizona
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Be informed of the investigational nature of the study and all pertinent aspects of the trial
Sign and provide written consent in accordance with institutional and federal guidelines
ECOG Performance status of 0-2
Recurrent or metastatic HER2-positive breast cancer (HER2 positive is defined per ASCO-CAP guidelines)
Adequate cardiac reserve (EF50%)
Serum creatinine 1.5 x institutional upper limit of normal (IULN), bilirubin 2.0, and an SGOT/SGPT/alkaline phosphatase 2.0 x IULN
Adequate bone marrow function (ANC 1000, Platelets 100,000/ml, Hemoglobin 10gm/dL)
Be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures
Been treated with pertuzumab previously (neoadjuvant or metastatic setting). Patients who weren't able to tolerate pertuzumab due to side effects can be eligible for study upon discussion with the study PI
No more than 2 lines of therapy in the metastatic disease setting

Exclusion Criteria

HER2 negative tumors
Prior treatment with T-DM1
Prior treatment with CDK 4/6 inhibitors
Known active CNS metastases or carcinomatous meningitis. Patients with stable CNS metastases including brain metastases who have completed a course of radiotherapy are eligible for the study provided they are clinically stable. However, oral corticosteroids for control of CNS symptoms are not allowed on study
Known documented or suspected hypersensitivity to the components of the study drug(s) or analogs
Uncontrolled systemic illness, including but not limited to ongoing or active infection
Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months
Be pregnant or breast feeding. Female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment and must agree to use effective contraception during the period of therapy
Concurrent hormonal or other anti-neoplastic therapy is not allowed. Patients can receive supportive therapy like bone-directed therapy including bisphosphonates or denosumab
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note